These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29944467)

  • 1. Effect of integrated yoga on anti-psychotic induced side effects and cognitive functions in patients suffering from schizophrenia.
    Verma M; Bhargav H; Varambally S; Raghuram N; Bn G
    J Complement Integr Med; 2018 Jun; 16(1):. PubMed ID: 29944467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.
    Lohr JB; Liu L; Caligiuri MP; Kash TP; May TA; Murphy JD; Ancoli-Israel S
    Schizophr Res; 2013 Oct; 150(1):289-96. PubMed ID: 23938173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference.
    Schouby Bock M; Nørgaard Van Achter O; Dines D; Simonsen Speed M; Correll CU; Mors O; Østergaard SD; Kølbæk P
    J Psychopharmacol; 2020 Aug; 34(8):820-828. PubMed ID: 32500804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic resolution among Chinese patients with schizophrenia and associated factors.
    Li CT; Su TP; Chou YH; Lee YC; Liu ME; Ku HL; Shan IK; Bai YM
    J Formos Med Assoc; 2010 May; 109(5):378-88. PubMed ID: 20497871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment.
    Chen KP; Lung FW
    Psychiatr Q; 2017 Dec; 88(4):787-796. PubMed ID: 28150091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism.
    Rudå D; Einarsson G; Matthiassen JB; Correll CU; Jensen KG; Klauber DG; Richard CJ; Andersen ASS; Krøigaard S; Møllegaard Jepsen JR; Fagerlund B; Winge K; Clemmesen LKH; Pagsberg AK; Paulsen RR; Fink-Jensen A
    Child Adolesc Ment Health; 2020 May; 25(2):79-94. PubMed ID: 32307841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study.
    Genç Y; Taner E; Candansayar S
    Adv Ther; 2007; 24(1):1-13. PubMed ID: 17526456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quality of life in patients with schizophrenia: a study of 100 cases].
    Zouari L; Thabet JB; Elloumi Z; Elleuch M; Zouari N; Maâlej M
    Encephale; 2012 Apr; 38(2):111-7. PubMed ID: 22516268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attitudes Toward Medications and the Relationship to Outcomes in Patients with Schizophrenia.
    Campbell AH; Scalo JF; Crismon ML; Barner JC; Argo TR; Lawson KA; Miller A
    Clin Schizophr Relat Psychoses; 2018; 12(1):12-22. PubMed ID: 26218237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
    Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
    J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia.
    Fervaha G; Agid O; Takeuchi H; Lee J; Foussias G; Zakzanis KK; Graff-Guerrero A; Remington G
    Schizophr Res; 2015 Feb; 161(2-3):351-6. PubMed ID: 25471015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
    Mulsant BH; Gharabawi GM; Bossie CA; Mao L; Martinez RA; Tune LE; Greenspan AJ; Bastean JN; Pollock BG
    J Clin Psychiatry; 2004 Dec; 65(12):1708-14. PubMed ID: 15641877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.